Therapeutic targeting of VEGF in the treatment of glioblastoma. - Wikidata - wikimedia - TriplyDB

Therapeutic targeting of VEGF in the treatment of glioblastoma.

Therapeutic targeting of VEGF in the treatment of glioblastoma.

http://www.wikidata.org/entity/Q38033241

about

Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM)Novel paracrine modulation of Notch-DLL4 signaling by fibulin-3 promotes angiogenesis in high-grade gliomas.Endothelial cells promote stem-like phenotype of glioma cells through activating the Hedgehog pathway.Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials.Pleiotropic effects of cancer cells' secreted factors on human stromal (mesenchymal) stem cells.Bevacizumab in high-grade gliomas: past, present, and future.Antitumour activity of 2-dihydroailanthone from the bark of Ailanthus altissima against U251.Interplay of VEGFa and MMP2 regulates invasion of glioblastoma.Cyclodextrin-based targeting strategies for tumor treatment.Levels of vascular endothelial growth factor and matrix metalloproteinase-9 proteins in patients with glioma.Isoprenaline/β2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis.VEGF promotes proliferation of human glioblastoma multiforme stem-like cells through VEGF receptor 2.Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study.

P2860

Q26853308-E1B87A41-6B47-47AF-B712-5DDEC6703F89 Q34256198-09E94A2D-E386-450A-82A0-6CEC7600DD82 Q34287855-725E7A20-24AD-4AD3-B4CB-065F7689EE46 Q34658803-FF53953F-D0B5-486C-87D0-1D4C8036ECD1 Q36824472-CB34DE3F-A2BC-411F-B5EC-598591026375 Q37372269-CE5E35F3-4CC3-4039-8EAB-858C5A394F11 Q38386873-8BD55402-A82A-43B1-943A-78B83AA9C3FA Q38787799-4C73C91B-C78D-413E-A436-8996E22DFE4E Q38957323-10165D78-38C2-4CFA-82D3-1BB7EACFF140 Q41195619-7A6EDE73-0FEE-48C7-890D-5534372DBDAC Q46116410-EDAB6CED-B586-4CCD-A7B7-E6BB1296BEC2 Q47158664-59526911-F58F-4BFD-8FCB-6D3B84C34A53 Q51822045-DDD13FE5-9223-4F64-A13E-270090648C30 Q52950126-4527B770-C1DF-478D-8BB0-D36ED2F40022

P2860

Therapeutic targeting of VEGF in the treatment of glioblastoma.

http://www.wikidata.org/entity/Q38033241

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Therapeutic targeting of VEGF in the treatment of glioblastoma.

@en

type

label

Therapeutic targeting of VEGF in the treatment of glioblastoma.

@en

prefLabel

Therapeutic targeting of VEGF in the treatment of glioblastoma.

@en

P1433

Q38033241-CE031D12-0123-43F2-9AD2-CC7A564DBA2C

P1476

Q38033241-3C354E05-3994-4092-9FBC-3A1DB8D339BA

P2093

Q38033241-0946E630-170F-4733-A9EC-98082BD6CB8A

Q38033241-56A83070-E35B-4C87-85EF-D8725163E199

Q38033241-67B8D5E7-D028-4ABD-BCDA-2CABAF171064

Q38033241-8EAC30B9-5C20-4833-AD63-0E512EF16235

Q38033241-D0E4B0F1-2929-44E5-ABC0-B1F53A4E0A14

P2860

Q38033241-01B07990-EB04-400D-9A1B-7B78254C9EA1

Q38033241-05227B03-EE1E-49F3-8F8F-9B9F4D72082A

Q38033241-055F7326-87D7-4750-8AD1-7FF3CB6C669D

Q38033241-0946BD65-FC97-4EA2-905D-1ED7896B66B8

Q38033241-0AE68B9A-FF3E-41DF-8F53-CAF522FC12AF

Q38033241-0B7CFD05-3559-4842-9867-35776F8C1A6A

Q38033241-0C8173C8-AA82-4ABC-A884-B7980AB11164

Q38033241-10D536C2-439C-4FA2-8792-41D97B6FEA7E

Q38033241-13A8586A-999D-46AC-ACFA-A1B8B42603AE

Q38033241-14A45166-F175-49A5-AAE5-21116BC9E074

P304

Q38033241-6A37A033-047C-42B1-B08D-09D5CFE171A5

P31

Q38033241-E198EB27-A9B6-41B9-AD71-941DDA4CFB27

P356

Q38033241-1E157218-8761-4377-B56E-A7E45A63AB90

P407

Q38033241-C2EA5B93-C2F5-48DE-A86F-1CECFF823E86

P433

Q38033241-88444523-4CFE-40E5-9104-AD806A8B46B0

P478

Q38033241-C68DB7DD-101F-4607-88C9-7655744602F9

P577

Q38033241-F5C2B0F3-F9DF-409D-ABD0-C82C70404B9A

P698

Q38033241-9BAB8B5F-A2A9-4E07-9DDF-B38F50990835

P356

14728222.2012.711817

P1433

Expert Opinion on Therapeutic Targets

P1476

Therapeutic targeting of VEGF in the treatment of glioblastoma.

@en

P2093

Candece L Gladson

http://www.w3.org/2001/XMLSchema#string

Dolores Hambardzumyan

http://www.w3.org/2001/XMLSchema#string

Ichiro Nakano

http://www.w3.org/2001/XMLSchema#string

Lizbeth Robles Irizarry

http://www.w3.org/2001/XMLSchema#string

Manmeet S Ahluwalia

http://www.w3.org/2001/XMLSchema#string

P2860

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

The role of pericytes in blood-vessel formation and maintenance

Combining antiangiogenics to overcome resistance: rationale and clinical experience

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

The biology of VEGF and its receptors

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Signal transduction to hypoxia-inducible factor 1

P304

973-984

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2012.711817

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22876981

http://www.w3.org/2001/XMLSchema#string